US Pharma MarketingThe post Ascletis receives FDA clearance for Phase I trial of obesity treatment appeared first on Clinical Trials Arena.
Ascletis receives FDA clearance for Phase I trial of obesity treatment
Ascletis Pharma has received investigational new drug (IND) clearance from the FDA to initiate a Phase I study of ASC35 for obesity. The study aims to evaluate ASC35’s safety, tolerability, pharmacokinetics and pharmacodynamics. ASC35 was independently discovered and developed using Ascletis’ AISBDD platform. Credit: Sai Thaw Kyar / Shutterstock.com. Ascletis Pharma has received investigational new drug (IND) clearance from the US Food and Drug Administration (FDA) to initiate a Phase I study of ASC35 for obesity. ASC35 is a once-monthly subcutaneous (SQ) glucagon-like peptide-1 receptor/glucose-dependent insulinotropic polypeptide receptor (GLP-1R/GIPR) dual peptide agonist. LOA and PTSR Model (Clesacostat Tromethamine +…
Ascletis Pharma has received investigational new drug (IND) clearance from the FDA to initiate a Phase I study of ASC35 for obesity.
Source: Clinical Trials Arena